Virtual Library
Start Your Search
Y. Jin
Author of
-
+
P3.02a - Poster Session with Presenters Present (ID 470)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02a-024 - Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4-ALK Translocation with Adnexal Metastasis (ID 3981)
14:30 - 14:30 | Author(s): Y. Jin
- Abstract
Background:
Lung cancer with ovarian metastasis or adnexal metastasis harboring anaplastic lymphoma kinase gene (ALK) translocation is rare. Crizotinib, a novel anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, has already shown an impressive single-agent activity in ALK-positive lung cancer.
Methods:
Our case is the first report of crizotinib effective for ALK-positive adenocarcinoma with adnexal metastasis. A 33-year-old woman was diagnosed with adnexal metastasis from non-small cell lung cancer (NSCLC). Histological examination of the tumors showed lung adenocarcinoma. The right lung biopsy tissue and left adnexal mass biopsy tissue were both revealed the presence of an ALK rearrangement by Ventana (D5F3) ALK immunohistochemistry (IHC) assay (Ventana Medical Systems, Roche, Inc).
Results:
The patient experienced a remarkable tumor response to crizotinib treatment.Figure 1
Conclusion:
Although the adnexal location is an uncommon metastasis site from lung cancer, oncologists should be aware of the possibility of such metastasis for female patients with ALK rearrangement NSCLC. Considering this remarkable response, we conclude that the presence of adnexal metastasis in NSCLC patients with ALK rearrangement should be attentive.
